Hutchison China MediTech is a biopharmaceutical company, engaging in the research, development, manufacture and sale of pharmaceuticals and healthcare products. It operates through Innovation Platform and Commercial Platform segments. The Company provides drug research and development services and develops, manufactures, distributes, markets and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. It also develops clinical drug candidates, including AZD6094 that is in Phase II clinical trial for treating non-small cell lung, colorectal and gastric cancer; Fruquintinib, which is in Phase III clinical trial for the treatment of colorectal, non-small cell lung and gastric cancer; Sulfatinib, a Phase II clinical trial product for neuroendocrine tumors and thyroid cancers; and Epitinib for the treatment of non-small cell lung cancer that is in Phase Ib clinical trial.